REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on stubborn blood cancer
Disease control OngoingThis study is testing whether adding the drug ipilimumab to the approved drug nivolumab can help control Hodgkin lymphoma that has come back or stopped responding to other treatments. It will involve about 13 adults whose cancer got worse after a prior type of immunotherapy. Part…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug duo tested in fight against stubborn blood cancers
Disease control OngoingThis early-phase trial is testing the safety and best dose of a two-drug combination (selinexor and choline salicylate) for adults with advanced blood cancers that have returned or stopped responding to standard treatments. The study includes patients with non-Hodgkin lymphoma, H…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New hope for Tough-to-Treat hodgkin lymphoma: immune drug combo trial shows promise
Disease control OngoingThis study is testing a two-part treatment for Hodgkin lymphoma that has come back or stopped responding to initial therapy. It combines an immunotherapy drug (nivolumab) that helps the immune system fight cancer with a standard chemotherapy regimen. The goal is to control the ca…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC